{"doi":"10.1109/mpuls.2024.3353668","title":"Breakthroughs in Brain Implants","abstract":null,"journal":"IEEE Pulse","year":2023,"id":626772,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1621465,"name":"Zara Abrams","orcid":"0000-0001-7782-2078","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Breakthroughs in Brain Implants","abstract":"In 2023, Brain implants got a big boost. Neuralink, Elon Musk's startup, began recruiting for its first clinical trial for paralysis patients; Precision Neuroscience received breakthrough designation from the Food and Drug Administration (FDA), allowing it to fast-track its own trials. Meanwhile, scientific advances are revealing promising new applications for such devices, including more comprehensive restoration of speech, sight, hearing, and movement to people who have lost those abilities, as well as help for psychiatric conditions, such as eating disorders and depression.","is_dataset_classified":null,"base_score":1.791759469228055,"endowment":1.791759469228055,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38386566","pmcid":null,"openalex_id":"https://openalex.org/W4392063176","authors":[],"funders":[],"total_grants":0,"fwci":0.9208,"citation_percentile":0.77173534,"influential_citations":0,"citation_trend":[{"year":2025,"count":5}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-029","oa_locations":[{"url":"http://xplorestaging.ieee.org/ielx7/5454060/10443790/10443814.pdf?arnumber=10443814","host_type":"publisher"},{"url":"https://doi.org/10.1109/mpuls.2024.3353668","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38386566","host_type":"repository"}],"fields_of_study":["Neurological disorders and treatments","Neuroscience and Neural Engineering","Neuroscience and Neuropharmacology Research"],"mesh_terms":["Brain","Clinical Trials as Topic","Humans","United States","United States Food and Drug Administration","Device Approval","Prostheses and Implants"],"keywords":["Food and drug administration","Retinal implant","Clinical trial","Depression (economics)","Medicine","Psychiatry","Neuroscience","Psychology","Implant","Medical emergency","Surgery","Pathology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T15:11:48.989902Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}